ライフサイエンスコーパス: dipeptidyl

1 Dipeptidyl (acyloxy)methyl ketones (AOMKs) were function

2 The plasmodial enzyme dipeptidyl aminopeptidase 1 (DPAP1) was enriched from pa

3 function that is structurally related to the dipeptidyl aminopeptidase and cell adhesion protein CD26

4 h the signal sequence from the yeast protein dipeptidyl aminopeptidase B, so that the resulting prote

5 and parasite-selective delivery of a potent dipeptidyl aminopeptidase inhibitor.

6 The proline-specific dipeptidyl aminopeptidase IV (DPP IV, DPP-4, CD26), wide

7 It has recently been reported that dipeptidyl aminopeptidase X (DPPX) interacts with the vo

8 DPPX is unlikely to function as a protease (dipeptidyl aminopeptidase).

9 In particular, for dipeptidyl aminopeptidase, an SP that is recognized by t

10 Dipeptidyl aminopeptidase-like protein 6 (DPP6) was firs

11 The dipeptidyl aminopeptidase-like protein DPPX (DPP6) assoc

12 d Kv channel-interacting protein (KChIP) and dipeptidyl aminopeptidase-like protein subunits comprise

13 2,6-Dipeptidyl-anthraquinones are a promising class of nucle

14 the proteasomal inhibition mechanism of the dipeptidyl boronate N-(4-morpholine)carbonyl-beta-(1-nap

15 rtezomib (also known as PS-341/Velcade) is a dipeptidyl boronic acid that has recently been approved

16 e pH-dependent cyclization prevalent in most dipeptidyl boronic acids that attenuates their potency a

17 f inhibitors of aminopeptidases (amastatin), dipeptidyl carboxypeptidase (captopril), and neutral end

18 a lesser involvement of aminopeptidases and dipeptidyl carboxypeptidase.

19 of a diastereomeric pair of N-Fmoc-protected dipeptidyl diazoketones.

20 (EGFP)-marked HBC-3 cells into wild-type or dipeptidyl dipeptidase IV (DPPIV) knockout blastocysts.

21 n T2, before generating the l-Phe-l-Ser-S-T2 dipeptidyl enzyme intermediate.

22 We describe herein the optimization of dipeptidyl inhibitors of norovirus 3C-like protease usin

23 paper describes the design and synthesis of dipeptidyl N,N-dimethyl glutaminyl fluoromethyl ketones

24 The dipeptidyl peptidase (DPP) 4 family includes four enzyme

25 The intracellular peptidases dipeptidyl peptidase (DPP) 8 and DPP9 are involved in mu

26 boronic dipeptide, PT-100 (Val-boro-Pro), a dipeptidyl peptidase (DPP) inhibitor, has been shown to

27 Dipeptidyl peptidase (DPP)-4 inhibition is a glucose-low

28 The binding kinetics and thermodynamics of dipeptidyl peptidase (DPP)-4 inhibitors (gliptins) were

29 Dipeptidyl peptidase (DPP)-IV inhibitory peptides were p

30 tudies, CTL generated from mice deficient in dipeptidyl peptidase 1 (DPP1) were used to investigate t

31 Dipeptidyl peptidase 10 (DPP10) shares with DPP6 a high

32 We found that the cellular peptidases dipeptidyl peptidase 3 (DPP-3) and thimet oligopeptidase

33 ke WTX, PALB2, and SQSTM1, we found that the dipeptidyl peptidase 3 (DPP3) protein binds KEAP1 via an

34 as a mediator of the therapeutic effects of dipeptidyl peptidase 4 (DPP-4) inhibition (vildagliptin)

35 n), was identified as a potent and selective dipeptidyl peptidase 4 (DPP-4) inhibitor with an excelle

36 perglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear.

37 antidiabetic incretin-based drugs, including dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-l

38 outcomes with alogliptin, a new inhibitor of dipeptidyl peptidase 4 (DPP-4), as compared with placebo

39 omaltase, glucose transporter 2 (GLUT2), and dipeptidyl peptidase 4 (DPP-4), as well as that of the p

40 Previous analysis of mice lacking the enzyme dipeptidyl peptidase 4 (DPP4(-/-) mice), a biomedically

41 ted proteins such as the tetraspanin CD9 and dipeptidyl peptidase 4 (DPP4) along with multiple endoso

42 ory syndrome coronavirus (MERS-CoV) utilizes dipeptidyl peptidase 4 (DPP4) as an entry receptor.

43 ory syndrome coronavirus (MERS-CoV) utilizes dipeptidyl peptidase 4 (DPP4) as an entry receptor.

44 r (Gipr)-deficient mice receiving background dipeptidyl peptidase 4 (DPP4) inhibitor treatment were c

45 However, whether increased dipeptidyl peptidase 4 (DPP4) is involved in the pathoge

46 Dipeptidyl peptidase 4 (DPP4) is the receptor for cell b

47 MERS-CoV to the cell surface entry receptor dipeptidyl peptidase 4 (DPP4) occurs via S1(B) We now de

48 th Jamaican fruit bat (Artibeus jamaicensis) dipeptidyl peptidase 4 (DPP4) receptor and MERS-CoV repl

49 avirus (MERS-CoV) binds to cellular receptor dipeptidyl peptidase 4 (DPP4) via the spike (S) protein

50 Recently, the MERS-CoV receptor dipeptidyl peptidase 4 (DPP4) was identified and the spe

51 ions with the MERS-CoV cell surface receptor dipeptidyl peptidase 4 (DPP4), and evolutionary mechanis

52 receptor for MERS-CoV has been identified as dipeptidyl peptidase 4 (DPP4), the mouse DPP4 homologue

53 Liver microfragments from dipeptidyl peptidase 4 (DPP4)-deficient rats were transp

54 Taken together, our results point toward dipeptidyl peptidase 4 (DPP4)-dependent endosomal uptake

55 binding of the RBD to its cellular receptor, dipeptidyl peptidase 4 (DPP4).

56 , 4, 5, 13, and 14; sucrase isomaltase (SI); dipeptidyl peptidase 4 (Dpp4); glucose transporter type

57 Dipeptidyl peptidase 4 (DPP4, CD26) is a protease that c

58 Dipeptidyl peptidase 4 (DPP4, CD26), a type II transmemb

59 hree different epitopes in the RBD and human dipeptidyl peptidase 4 (hDPP4) interface with subnanomol

60 V after adenovirus transduction of the human dipeptidyl peptidase 4 (hDPP4) receptor and then analyze

61 Human dipeptidyl peptidase 4 (hDPP4) was recently identified a

62 ike peptide 1 [GLP-1] analogue) or enhancer (dipeptidyl peptidase 4 [DPP4] inhibitor).

63 t cells were identified as a major source of dipeptidyl peptidase 4 and we also found that skin mast

64 We further show dipeptidyl peptidase 4 expression, MERS-CoV replication,

65 Previous trial results have suggested that dipeptidyl peptidase 4 inhibitor (DPP4i) use might incre

66 rdiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patie

67 ascular safety of alogliptin, a nonselective dipeptidyl peptidase 4 inhibitor.

68 Dipeptidyl peptidase 4 inhibitors had an increased risk

69 ingestion and is critical for the actions of dipeptidyl peptidase 4 inhibitors that enhance GLP-1 lev

70 ike peptide 1 mimetics, amylin mimetics, and dipeptidyl peptidase 4 inhibitors), in addition to diet

71 nd 330) that match the human sequence in the dipeptidyl peptidase 4 receptor, making mice susceptible

72 MERS-CoV antigen; double immunostaining with dipeptidyl peptidase 4 showed colocalization in scattere

73 Dipeptidyl peptidase 4 was found to be expressed in mast

74 der enzymes (lactase, sucrase-isomaltase and dipeptidyl peptidase 4) and visible subepithelial and sm

75 ss spectrometry analysis revealed that DPP4 (dipeptidyl peptidase 4) was selectively expressed on the

76 corresponding oxopeptides toward cleavage by dipeptidyl peptidase 4, the principal regulator of their

77 lmonary expression of the MERS-CoV receptor, dipeptidyl peptidase 4, was similar in marmosets and mac

78 ns, the neural cell adhesion molecule L1 and dipeptidyl peptidase 4, were further studied.

79 of incretin mimetic drugs and inhibitors of dipeptidyl peptidase 4, which degrades GLP-1.

80 Trials of inhibitors of dipeptidyl peptidase 4, which enhance the effect of endo

81 tors expressing the human host-cell receptor dipeptidyl peptidase 4.

82 itute or an inhibitor of the serine protease dipeptidyl peptidase 4.

83 cludens-1, mucins-1 and -2, antigen A33, and dipeptidyl peptidase 4.

84 stasis: neural cell adhesion molecule L1 and dipeptidyl peptidase 4.

85 romal cell-derived factor-1-degrading enzyme dipeptidyl peptidase 4.

86 racting proteins (KChIPs) and transmembrane, dipeptidyl peptidase 6 and 10 (DPP6/10) accessory subuni

87 including dipeptidyl peptidase IV (DPP IV), dipeptidyl peptidase 8 (DPP8), fibroblast activation pro

88 Here we identified the cytosolic dipeptidyl peptidase 9 (DPP9) as a SUMO1 interacting pro

89 lose FAP homologues dipeptidyl peptidase IV, dipeptidyl peptidase 9, and prolyl oligopeptidase.

90 se in gelatinase activity, whereas levels of dipeptidyl peptidase activity remained unchanged.

91 Both proteases display dipeptidyl peptidase activity, but FAP alone has endopep

92 types of EDTA-resistant protease activities: dipeptidyl peptidase and a 170-kDa gelatinase activity.

93 Like the closely related dipeptidyl peptidase DPPIV, the extracellular domain of

94 rectly inhibits the activity of MMP20, KLK4, dipeptidyl peptidase I (DPPI) (an in vitro activator of

95 The cysteine protease dipeptidyl peptidase I (DPPI) activates granule-associat

96 Dipeptidyl peptidase I (DPPI) is a cysteine aminopeptida

97 Dipeptidyl peptidase I (DPPI) is a cysteine protease req

98 Dipeptidyl peptidase I (DPPI) is a lysosomal cysteine pr

99 e injected TxA into ileal loops in PAR(2) or dipeptidyl peptidase I (DPPI) knockout mice or in wild-t

100 In this study, we show that the absence of dipeptidyl peptidase I (DPPI), a lysosomal cysteine prot

101 the lysosomal cysteine protease cathepsin C/dipeptidyl peptidase I (DPPI).

102 Cathepsin C, or dipeptidyl peptidase I, is a lysosomal cysteine protease

103 n inactivating mutation in the gene encoding dipeptidyl peptidase I, resulting in neutrophils lacking

104 aring features like propeptide processing by dipeptidyl peptidase I, storage, and release as an activ

105 as not delayed in perforin-deficient mice or dipeptidyl peptidase I-deficient mice, which fail to pro

106 Dipeptidyl peptidase III (DPP III) is one of the most im

107 Dipeptidyl peptidase IV (DP-IV) is a cell surface serine

108 Dipeptidyl peptidase IV (DP-IV), a member of the prolyl

109 6)PAL) and GIP(Lys(37)PAL) were resistant to dipeptidyl peptidase IV (DPP IV) degradation.

110 Dipeptidyl peptidase IV (DPP IV) is a ubiquitous membran

111 Binding of plasminogen type II (Pg 2) to dipeptidyl peptidase IV (DPP IV) on the surface of the h

112 method to a variety of proteases, including dipeptidyl peptidase IV (DPP IV), dipeptidyl peptidase 8

113 ained lactam aminoboronic acid inhibitors of dipeptidyl peptidase IV (DPP IV; E.C. 3.4.14.5).

114 gorous steady state enzyme kinetic assay for dipeptidyl peptidase IV (DPP IV; E.C. 3.4.14.5).

115 e synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-4) for the treatment of typ

116 novel aminopiperidine-fused imidazopyridine dipeptidyl peptidase IV (DPP-4) inhibitor 1 has been dev

117 ered as potent, selective, and orally active dipeptidyl peptidase IV (DPP-4) inhibitors by extensive

118 Dipeptidyl peptidase IV (DPP-IV) belongs to a family of

119 Dipeptidyl peptidase IV (DPP-IV) degrades the incretin h

120 e synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-IV) for the treatment of ty

121 e synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-IV) for the treatment of ty

122 agon-like peptide-1 (GLP-1) degrading enzyme dipeptidyl peptidase IV (DPP-IV) have been shown to be e

123 Xanthine oxidase (XO) and dipeptidyl peptidase IV (DPP-IV) inhibition by amino aci

124 acid linked l-cis-4,5-methanoprolinenitrile dipeptidyl peptidase IV (DPP-IV) inhibitors led to the i

125 tent angiotensin converting enzyme (ACE) and dipeptidyl peptidase IV (DPP-IV) inhibitory and oxygen r

126 Nine novel dipeptidyl peptidase IV (DPP-IV) inhibitory peptides (FL

127 ts (DOE) was used to optimise the release of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides dur

128 of 72 dietary proteins to act as a source of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides.

129 as no significant effect of pH regulation on dipeptidyl peptidase IV (DPP-IV) properties.

130 These peptides are known to act as preferred dipeptidyl peptidase IV (DPP-IV) substrates.

131 l screening was performed against the target dipeptidyl peptidase IV (DPP-IV) to identify good chemic

132 HSA), other components, such as the protease dipeptidyl peptidase IV (DPP-IV), possibly contribute to

133 N-terminal sequence-specific serine protease dipeptidyl peptidase IV (DPP-IV).

134 Dipeptidyl peptidase IV (DPP-IV; E.C. 3.4.14.5), a serin

135 Dipeptidyl peptidase IV (DPP4) deactivates glucose-regul

136 Dipeptidyl peptidase IV (DPP4) inhibitors are emerging a

137 Dipeptidyl peptidase IV (DPP4/CD26) and seprase/fibrobla

138 Dipeptidyl peptidase IV (DPPIV) activity was quantified

139 epatocytes can give rise to SHPCs, rats with dipeptidyl peptidase IV (DPPIV) chimeric livers, which h

140 expression of CD26, especially its intrinsic dipeptidyl peptidase IV (DPPIV) enzyme activity, results

141 ine (C5-Pro-Pro) analogues was discovered as dipeptidyl peptidase IV (DPPIV) inhibitors as a potentia

142 Dipeptidyl peptidase IV (DPPIV) is a serine protease wit

143 as evaluated by injecting cell isolates from dipeptidyl peptidase IV (DPPIV) positive (DPPIV+) Fische

144 Dipeptidyl peptidase IV (DPPIV), a cell surface serine p

145 ddresses the hypothesis that the activity of dipeptidyl peptidase IV (DPPIV), an enzyme that inactiva

146 expression of a cell transplantation marker, dipeptidyl peptidase IV (DPPIV), and GFP.

147 FAPalpha exhibits a dipeptidyl peptidase IV (DPPIV)-like fold, featuring an

148 g the protocol of injecting hepatocytes from dipeptidyl peptidase IV (DPPIV)-positive donors into ret

149 ffects of HIR on engraftment of transplanted dipeptidyl peptidase IV (DPPIV)-positive hepatocytes in

150 rotein (FAP) is a serine protease related to dipeptidyl peptidase IV (DPPIV).

151 ed structure of AprA has similarity to human dipeptidyl peptidase IV (DPPIV).

152 y inhibition of the closely related protease dipeptidyl peptidase IV (DPPIV).

153 proteins after enzymatic digestion, against dipeptidyl peptidase IV (DPPIV); an enzyme known to deac

154 Lung endothelial dipeptidyl peptidase IV (DPPIV/CD26) is a vascular addre

155 Wild-type (dipeptidyl peptidase IV [DPPIV(+)]) embryonic day (ED) 1

156 hepatocyte colonies with strong canalicular dipeptidyl peptidase IV activity.

157 atrophy and marked up-regulation of mucosal dipeptidyl peptidase IV and PepT1 messenger RNA.

158 tology and expression of brush border enzyme dipeptidyl peptidase IV and peptide transporter PepT1 me

159 both analogues were completely resistant to dipeptidyl peptidase IV degradation.

160 assays based on F344 recipient rats lacking dipeptidyl peptidase IV enzyme activity to identify tran

161 ibited APCE with a K(i) of 54 microM but not dipeptidyl peptidase IV even at 2 mM.

162 vivo, but this effect was only detected with dipeptidyl peptidase IV inhibition, while mucosal respon

163 ulocyte-colony stimulating factor (G-CSF), a dipeptidyl peptidase IV inhibitor (DPP-4i), and a proton

164 in medicinal chemistry applications such as dipeptidyl peptidase IV inhibitors.

165 tal liver cells were transplanted into adult dipeptidyl peptidase IV knockout mice and differentiated

166 One week post-MMC treatment, dipeptidyl peptidase IV negative host rats were given a

167 vivo and mature into hepatocytes expressing dipeptidyl peptidase IV or fumarylacetoacetate hydrolase

168 ntained large clusters of sinusoids lined by dipeptidyl peptidase IV positive endothelial cells coexp

169 newborn, or adult total liver isolates from dipeptidyl peptidase IV positive rats.

170 ent on degradation by neutral endopeptidase, dipeptidyl peptidase IV, and aminopeptidase P.

171 ts but does not inhibit close FAP homologues dipeptidyl peptidase IV, dipeptidyl peptidase 9, and pro

172 Three groups of mutant F344 dipeptidyl peptidase IV-deficient (DPPIV(-)) rats were r

173 , we used transplanted cells as reporters in dipeptidyl peptidase IV-deficient mice.

174 hepatocytes were transplanted into syngeneic dipeptidyl peptidase IV-deficient rats followed by histo

175 F344 rat hepatocytes with or without DAR in dipeptidyl peptidase IV-deficient rats.

176 ter transplanting syngeneic hepatocytes into dipeptidyl peptidase IV-deficient rats.

177 t and proliferation of transplanted cells in dipeptidyl peptidase IV-deficient rats.

178 hepatocytes were transplanted into syngeneic dipeptidyl peptidase IV-deficient rats.

179 d Fischer 344 rat hepatocytes into syngeneic dipeptidyl peptidase IV-deficient rats.

180 r repopulation by histochemical staining for dipeptidyl peptidase IV.

181 ll surface multifunctional glycoprotein CD26/dipeptidyl peptidase IV.

182 Conversely, DPP-4 Asp663 stabilizes dipeptidyl peptidase substrate binding and permits tight

183 marked TSS energy for both endopeptidase and dipeptidyl peptidase substrates, and structural modeling

184 Dipeptidyl peptidase type IV (DppIV) enzymes are broadly

185 Dipeptidyl peptidase-4 (CD26, DPP4) inhibitors are the m

186 Dipeptidyl peptidase-4 (DDP4) inhibitors target the enzy

187 te effects of treatment with vildagliptin on dipeptidyl peptidase-4 (DPP-4) activity, glucagon-like p

188 nes are terminated via enzymatic cleavage by dipeptidyl peptidase-4 (DPP-4) and through renal clearan

189 Fibroblast activation protein (FAP) and dipeptidyl peptidase-4 (DPP-4) are highly homologous ser

190 nguish FAP from other prolyl peptidases like dipeptidyl peptidase-4 (DPP-4) have not been developed.

191 (GLP-1) receptor agonists and inhibitors of dipeptidyl peptidase-4 (DPP-4) have shown pleiotropic ef

192 in this subgroup who also had baseline serum dipeptidyl peptidase-4 (DPP-4) higher than the populatio

193 od, crossover study in 24 patients with T2D, dipeptidyl peptidase-4 (DPP-4) inhibition and its glucos

194 bese mice (ob/ob), 45h was as effective as a dipeptidyl peptidase-4 (DPP-4) inhibitor at reducing pea

195 Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor in clinical use

196 Linagliptin is a dipeptidyl Peptidase-4 (DPP-4) inhibitor that inhibits t

197 In this regard, dipeptidyl peptidase-4 (DPP-4) inhibitors have recently

198 acological levels of GLP-1 activity, whereas dipeptidyl peptidase-4 (DPP-4) inhibitors increase conce

199 1 (GLP-1) secretion, on glucose lowering by dipeptidyl peptidase-4 (DPP-4) inhibitors is unclear.

200 Dipeptidyl peptidase-4 (DPP-4) inhibitors prevent degrad

201 Recent studies concluded that dipeptidyl peptidase-4 (DPP-4) inhibitors provide glycem

202 ike peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors represent 2 di

203 etformin, thiazolidinediones, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium-gl

204 italized heart failure (hHF) associated with dipeptidyl peptidase-4 (DPP-4) inhibitors, creating unce

205 GLP-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, which inhibit

206 bute to the mechanism by which inhibitors of dipeptidyl peptidase-4 (DPP-4) lower postprandial glucos

207 on of enzymatic degradation by inhibition of dipeptidyl peptidase-4 (DPP-4) promotes glycemic reducti

208 ears to prevent apoptosis, and inhibition of dipeptidyl peptidase-4 (DPP-4), which cleaves GLP-1, is

209 GLP-1 and GLP-2 are both cleaved by dipeptidyl peptidase-4 (DPP-4); hence, inhibition of DPP

210 nfect both humans and dromedary camels using dipeptidyl peptidase-4 (DPP4) as its receptor.

211 icyte interactions, as well as the effect of dipeptidyl peptidase-4 (DPP4) inhibitor on CD in endothe

212 The incretin-based therapies, dipeptidyl peptidase-4 (DPP4) inhibitors and glucagon-li

213 viously disclosed azolopyrimidine containing dipeptidyl peptidase-4 (DPP4) inhibitors led us to focus

214 Dipeptidyl peptidase-4 (DPP4) inhibitors used for the tr

215 Dipeptidyl peptidase-4 (DPP4) was recently identified as

216 Blocking dipeptidyl peptidase-4 activity resulted in decreased po

217 gon like peptide-1 levels and a reduction in dipeptidyl peptidase-4 activity.

218 antidiabetic agents such as sulfonylureas or dipeptidyl peptidase-4 antagonists, which promote glucos

219 We investigated whether chronic dipeptidyl peptidase-4 inhibition by sitagliptin protect

220 At 30 minutes recovery, dipeptidyl peptidase-4 inhibition mitigated the postisch

221 dy, we compared the safety and efficacy of a dipeptidyl peptidase-4 inhibitor (sitagliptin) plus basa

222 adverse events for those associated with the dipeptidyl peptidase-4 inhibitor sitagliptin and the glu

223 The dipeptidyl peptidase-4 inhibitor sitagliptin, an antidia

224 The addition of dipeptidyl peptidase-4 inhibitor therapy with sitaglipti

225 creasing thiazolidinedione use and increased dipeptidyl peptidase-4 inhibitor use over time (P<0.001)

226 f newer antihyperglycemic medications in the dipeptidyl peptidase-4 inhibitor, glucagon-like peptide-

227 o assess the effectiveness of linagliptin, a dipeptidyl peptidase-4 inhibitor, in elderly patients wi

228 gonist, versus maximum approved doses of the dipeptidyl peptidase-4 inhibitor, sitagliptin, or the th

229 CI 1.15-1.76; six trials), intermediate with dipeptidyl peptidase-4 inhibitors (1.25, 1.08-1.45; two

230 ndings from preclinical studies suggest that dipeptidyl peptidase-4 inhibitors and proton-pump inhibi

231 ials supporting the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and some glucagon-like

232 lucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors are commonly used for

233 There are also concerns that dipeptidyl peptidase-4 inhibitors could cause cancer, gi

234 ncretin system, GLP-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors for 26 +/- 8 months be

235 1 analogs, alpha-glucosidase inhibitors, and dipeptidyl peptidase-4 inhibitors were associated with w

236 diones were used in 6.6% of HF patients, and dipeptidyl peptidase-4 inhibitors were used in 5.1%, wit

237 n-like peptide [GLP]-1 receptor agonists and dipeptidyl peptidase-4 inhibitors) have proven efficacy

238 s continued taking metformin with or without dipeptidyl peptidase-4 inhibitors.

239 the glucagon-like peptide-1 mimetics and the dipeptidyl peptidase-4 inhibitors.

240 t for 6-12 months and once-weekly tablets of dipeptidyl peptidase-4 inhibitors.

241 essing enzyme corin and BNP-degrading enzyme dipeptidyl peptidase-4 were reduced in HF versus normal,

242 We identified a single protein, CD26 (dipeptidyl peptidase-4).

243 otentially by producing excessive amounts of Dipeptidyl peptidase-4, a protease that is a target of d

244 s augmented by pharmacological inhibition of dipeptidyl peptidase-4.

245 cluding CD103(+) and CD11b(hi) cDCs, express dipeptidyl peptidase-4/CD26.

246 -glucosidase (37.8%), alpha-amylase (35.6%), dipeptidyl peptidase-IV (34.4%), reactive oxygen species

247 uggest a variety of bioactivities, including dipeptidyl peptidase-IV (DPP-IV) and angiotensin convert

248 wever, its rapid degradation by enzymes like dipeptidyl peptidase-IV (DPP-IV) and neutral endopeptida

249 P-1 is short because of rapid degradation by dipeptidyl peptidase-IV (DPP-IV) and renal clearance.

250 f GLP-1 is short due to rapid degradation by dipeptidyl peptidase-IV (DPP-IV) and renal clearance.

251 Dipeptidyl peptidase-IV (DPP-IV) inhibitors are poised t

252 Dipeptidyl peptidase-IV (DPP-IV) is a serine protease in

253 P-1, due to its resistance to degradation by dipeptidyl peptidase-IV (DPP-IV).

254 ate or propionate increased DBS, enhanced by dipeptidyl peptidase-IV (DPPIV) inhibition, at the same

255 s are a good source of natural inhibitors of dipeptidyl peptidase-IV and prolyl endopeptidase and cou

256 The dipeptidyl peptidase-IV inhibitor saxagliptin (Onglyza)

257 tivities and clinical variants, for example, dipeptidyl peptidase-IV inhibitor-associated noninflamma

258 d 1-beta-fructofuranosyl nystose) are potent dipeptidyl peptidase-IV inhibitors as well as peroxisome

259 ction of several serine proteases, including dipeptidyl peptidase-IV, neutrophil elastase, matrix met

260 Protein biochemistry has identified dipeptidyl peptidase-like protein 6 (DPP6) as an auxilia

261 Dipeptidyl peptidase-like protein 6 (DPP6) is an auxilia

262 , the Ca(2+) binding proteins KChIPs and the dipeptidyl peptidase-like proteins (DPPLs) DPP6 (also kn

263 +) channel-interacting proteins (KChIPs) and dipeptidyl peptidase-like proteins (DPPLs).

264 ) channel-interacting proteins (KChIPs), and dipeptidyl peptidase-like proteins (DPPLs).

265 administration of an inhibitor of the enzyme dipeptidyl-peptidase (DPP4i), which prevents the cleavag

266 glucosyltransferase); butyrylcholinesterase; dipeptidyl-peptidase 4 (CD26, adenosine deaminase comple

267 Dipeptidyl-peptidase 4 (DPP-4) inhibitors are increasing

268 Acarbose, the dipeptidyl-peptidase 4-inhibitor sitagliptin, the glucag

269 The dipeptidyl-peptidase 6 gene has been associated with a n

270 We report that dipeptidyl-peptidase 6 interacts with a filopodia-associ

271 Dipeptidyl-peptidase 6 is an auxiliary subunit of Kv4-me

272 We find that the hippocampal neurons lacking dipeptidyl-peptidase 6 show a sparser dendritic branchin

273 dipeptidyl-peptidase 6 therefore has an unexpected but i

274 we employ knockdown and genetic deletion of dipeptidyl-peptidase 6 to reveal its importance for the

275 n, expression of sucrase isomaltase (SI) and dipeptidyl-peptidase IV (DPP-IV), two well known intesti

276 ow cytometry and histochemical estimation of dipeptidyl-peptidase IV enzyme activity of donor cells i

277 in juvenile and senescent rats deficient in dipeptidyl-peptidase IV.

278 yeast of Blastomyces dermatitidis elaborates dipeptidyl-peptidase IVA (DppIVA), a close mimic of the

279 inally, combination of DGAT1 inhibition with dipeptidyl-peptidase-4 (DPP-4) inhibition led to further

280 Fasting adipocytokines and dipeptidyl-peptidase-4 concentrations were measured.

281 Dipeptidyl-peptidase-4 levels increased after surgery (P

282 Dipeptidyl-peptidase-IV-deficient female rats received B

283 cell-base experiments with Kv4.2 and several dipeptidyl-peptidase-like protein-6 (DPPX) plasmid const

284 metabotropic glutamate receptor 5 (mGluR5), dipeptidyl-peptidase-like protein-6 (DPPX), and gamma-am

285 mined the putative novel contribution of the dipeptidyl-peptidase-like protein-6 DPP6-S to the gamma

286 Kv channel-interacting proteins (KChIPs) and dipeptidyl-peptidase-like proteins (DPLs: DPP6 or DPPX,

287 hannel interacting proteins (KChIPs) and the dipeptidyl-peptidase-like proteins (DPPLs) DPPX (DPP6) a

288 ulating the biophysical properties of Kv4.2: dipeptidyl-peptidase-like type II transmembrane proteins

289 Dipeptidyl peptidases (DP) 8 and 9 are homologous, cytop

290 ncy and high selectivity against the related dipeptidyl peptidases (DPPs) DPPIV, DPP9, DPPII, and pro

291 demonstrate that this effect is prevented by dipeptidyl peptidases (DPPs), which cleave NPY to its sh

292 ors that are selective for FAP over both the dipeptidyl peptidases (DPPs), with which it shares exope

293 The data support increasing evidence that dipeptidyl peptidases can regulate complex biologic syst

294 f dipeptide production processes mediated by dipeptidyl-peptidases (DPPs) should be beneficial for th

295 tein-alpha, antiplasmin-cleaving enzyme, and dipeptidyl prolyl peptidase 5) is expressed at high leve

296 ities of three compounds possessing a common dipeptidyl residue with different warheads, i.e., an ald

297 duct, but rather that the enzyme catalyzes a dipeptidyl transfer reaction in which some of the energy

298 been assumed to be a gamma-glutamylcysteine dipeptidyl transpeptidase (EC 2.3.2.15) and, more recent

299 s are gamma-glutamylcysteine (gamma-Glu-Cys) dipeptidyl transpeptidases that catalyze the synthesis o

300 The unusual Ala(4)-Phe(5) dipeptidyl ureido linkage was formed during in vitro ass